

Distribution Agreement signed with Helicon Health leading UK remote patient monitoring platform

Melbourne, Australia – 14 June 2022: Adherium Limited (“Adherium”; ASX: ADR), a leader in respiratory eHealth, remote patient monitoring and data management solutions, is pleased to announce it has signed its first UK distribution agreement with Helicon Health Ltd (“Helicon”) to sell the Hailie® sensor range and cloud data services.

Adherium’s Hailie digital smart inhaler attaches to a patient’s Asthma or COPD medication inhaler and connects via the Hailie app to Helicon’s comprehensive remote patient monitoring platform. The combination creates, for the first time, the most advanced quality care for respiratory patients that are on Virtual Wards, at home and in any other remote setting. Adherium’s Hailie sensors monitor medication adherence and the new, next generation sensors, provide actionable data about technique and physiology for the clinical team to make timely decisions on patient care.

Helicon Health is a medical technology development company, a NHS-focused contract research partner and specialised medical device accelerator. Helicon Health was originally spun-out from the UCL Centre for Health Informatics and Multi Professional Education (CHIME). Helicon Health is supporting integrated care systems in the development of “learning health systems” by enabling the ethical collection of real-world data for analysis and interpretation for real world evidence to inform translation into better outcomes for patients and more effective use of scarce resources.

Initially founded to support the care of those that require at home care for conditions such as cardiovascular disease, cancer, diabetes and dementia, Helicon has accelerated and expanded its offering for respiratory, paediatric, neo natal and trauma networks through partnerships to deliver healthcare virtually.

The signing of this distribution agreement for an initial three-year term follows the recent appointment of Francis White as Vice President of Global Business Development and cements Adherium’s growth strategy to partner with leading players globally across strategically important geographies especially in the USA and UK to expand its footprint and deliver enhanced remote patient care.



Tony Bowden, Chief Executive Office of Helicon Health commented, “This agreement with Adherium marks yet another milestone in our journey towards helping people live longer healthier lives. Supporting people with understanding and complying with the instructions for use of medications is fundamental to achieving the healthcare outcomes people young and old and all in between need – whilst at the same time helping health systems gain the best results from scarce resource.”

“This agreement with Helicon presents a significant opportunity to better serve the often-overlooked severe Asthma population and give a true and metric driven care pathway for COPD patients. The expertise of the team at Helicon will transform our market access in the UK, give us opportunities in ground-breaking care and accelerate adoption,” said Francis White, Global VP Business Development.

About Adherium (ASX: ADR)

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices, with more than 180,000 sold globally. Adherium’s Hailie platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management.

The Hailie solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium’s own broad range of sensors connected to respiratory medications. Adherium’s Hailie solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease.

Learn more at www.adherium.com

This ASX announcement was approved and authorised for release by the Board of Adherium.

Enquiries: WE Communications

WE-AUAdherium@we-worldwide.com